Masterclass: DTx Reimbursement: Navigating Medicare & Medicaid Coverage

Navigating the ever-evolving landscape of CMS coverage (Centers for Medicare & Medicaid Services) for digital therapeutics (DTx) in the US is challenging. Furthermore, the fragmented nature of reimbursement in the US, with coverage differing between states, means DTx providers are relying on selective contracts, and going state by state for coverage. Therefore, It is critical to stay up to date with current strategies and updates that CMS is introducing.
During this masterclass, Mike Pace (CEO & Founder at Palm Health), will cover updates to and the implications of new acts introduced by the CMS, including the Access to Prescription Digital Therapeutics Act, and the Patient Access to Critical Breakthrough Products Act.
If you are looking for effective strategies to secure coverage of your DTx solution in the US, this masterclass is for you!

• Targeting CMS Coverage: What states and market segments have the highest potential for DTx reimbursement with CMS?

• Updates to CMS Policies: What are the latest CMS policy developments, and how will these policy changes impact DTx coverage?

• Strategies of Engaging CMS: How to approach Medicare & Medicaid decision makers. What access negotiations and reimbursement contracts are best suited for successful engagement?

• Scaling Coverage Across States: What approaches should DTx be taking to help expand coverage across different states?

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.